港股异动|维他奶涨逾3%获独董累计增持近0.2%的公司股份
格隆汇7月12日丨维他奶(0345.HK)曾于6月20日午间公布年度业绩指,截至3月底止年度收入75.26亿港元,同比增约16%,增速与上年同期的21%相比有所下降。其中,中国内地的收入增长25%,与上年同期的38%有明显下降。
绩后维他奶连跌四日累跌近19%,后股价维持窄幅震荡,今日反弹涨3.37%,现报38.3港元,暂成交1.25亿港元,最新总市值406.8亿港元。

值得一提的是,维他奶自6月24日至上周四(4日)期间,获独董李国宝共计6次增持,其中上周连续三日累计增持100万股。经过6次增持后,李国宝的持股比例由0.57%升至0.75%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.